A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Active, not recruiting · Phase 3 · NCT06970743
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $1,600
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 153
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BGB-16673 (drug), Bendamustine (drug), Rituximab (drug), Methylprednisolone (drug), Chlorambucil (drug), Obinutuzumab (drug)
- Dates
- Started 2025-05-29; completion 2029-11-30
- Results posted
- Not yet
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab) in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to covalent Bruton tyrosine kinase inhibitor(s) (cBTKi).
From ClinicalTrials.gov, last updated 2026-08-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $1,600 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $1,600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.